Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Bosutinib in Adult Patients With Recurrent Glioblastoma
An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM)
Status: Enrolling
Updated:  10/18/2013
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Bosutinib in Adult Patients With Recurrent Glioblastoma
An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM)
Status: Enrolling
Updated: 10/18/2013
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Bosutinib in Adult Patients With Recurrent Glioblastoma
An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM)
Status: Enrolling
Updated:  10/18/2013
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Bosutinib in Adult Patients With Recurrent Glioblastoma
An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM)
Status: Enrolling
Updated: 10/18/2013
Massachusetts General Hospital
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Low-Dose Naltrexone for Glioma Patients
Effects of Low-Dose Naltrexone on Quality of Life in High-Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial
Status: Enrolling
Updated:  11/4/2013
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Low-Dose Naltrexone for Glioma Patients
Effects of Low-Dose Naltrexone on Quality of Life in High-Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial
Status: Enrolling
Updated: 11/4/2013
Duke Univ Med Ctr
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment
Status: Enrolling
Updated:  11/5/2013
UCSD San Diego
1055
mi
from 98109
La Jolla, CA
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment
Status: Enrolling
Updated: 11/5/2013
UCSD San Diego
1055
mi
from 98109
La Jolla, CA
Click here to add this to my saved trials
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment
Status: Enrolling
Updated:  11/5/2013
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment
Status: Enrolling
Updated: 11/5/2013
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment
Status: Enrolling
Updated:  11/5/2013
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment
Status: Enrolling
Updated: 11/5/2013
Beth Israel Deaconess Medical Center
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment
Status: Enrolling
Updated:  11/5/2013
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas
A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients With Malignant Gliomas Undergoing Radiotherapy With or Without Standard Chemotherapy Treatment
Status: Enrolling
Updated: 11/5/2013
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: Enrolling
Updated:  12/16/2013
UNC Lineberger Comprehensive Cancer Center
2329
mi
from 98109
Chapel Hill, NC
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Status: Enrolling
Updated: 12/16/2013
UNC Lineberger Comprehensive Cancer Center
2329
mi
from 98109
Chapel Hill, NC
Click here to add this to my saved trials
Tegaderm and Visual Evoked Potentials
A Pilot Study: Does Tegaderm Placement on Eyes to Prevent Lagophthalmos Affect Visual Evoked Potentials Data Latency and Amplitude
Status: Enrolling
Updated:  4/2/2014
University Hospital
2393
mi
from 98109
Newark, NJ
Tegaderm and Visual Evoked Potentials
A Pilot Study: Does Tegaderm Placement on Eyes to Prevent Lagophthalmos Affect Visual Evoked Potentials Data Latency and Amplitude
Status: Enrolling
Updated: 4/2/2014
University Hospital
2393
mi
from 98109
Newark, NJ
Click here to add this to my saved trials
Magnetic Resonance (MR) Imaging Study Using Ferumoxytol to Assess Early Tumor Response in Patients With Glioblastoma Multiforme
Early Assessment of Tumor Response to Therapy Using Ferumoxytol (Code 7228) as an MR Contrast Agent in Patients With Glioblastoma Multiforme
Status: Enrolling
Updated:  5/9/2014
Oregon Health and Science University
147
mi
from 98109
Portland, OR
Magnetic Resonance (MR) Imaging Study Using Ferumoxytol to Assess Early Tumor Response in Patients With Glioblastoma Multiforme
Early Assessment of Tumor Response to Therapy Using Ferumoxytol (Code 7228) as an MR Contrast Agent in Patients With Glioblastoma Multiforme
Status: Enrolling
Updated: 5/9/2014
Oregon Health and Science University
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion γδ T-Cells
Status: Enrolling
Updated:  5/9/2014
University of Alabama at Birmingham/Children's of Alabama
2079
mi
from 98109
Birmingham, AL
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion γδ T-Cells
Status: Enrolling
Updated: 5/9/2014
University of Alabama at Birmingham/Children's of Alabama
2079
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
Pilot Study to Compare Dynamic MR Imaging Changes in Patients With Recurrent High Grade Glioma, Receiving an Antiangiogenic Drug, Bevacizumab, Versus Dexamethasone. Dual Agent MR Imaging Study, Using Gadolinium and Ferumoxytol (Code 7228)
Status: Enrolling
Updated:  5/12/2014
Oregon Health and Science University
147
mi
from 98109
Portland, OR
Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
Pilot Study to Compare Dynamic MR Imaging Changes in Patients With Recurrent High Grade Glioma, Receiving an Antiangiogenic Drug, Bevacizumab, Versus Dexamethasone. Dual Agent MR Imaging Study, Using Gadolinium and Ferumoxytol (Code 7228)
Status: Enrolling
Updated: 5/12/2014
Oregon Health and Science University
147
mi
from 98109
Portland, OR
Click here to add this to my saved trials
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization
Status: Enrolling
Updated:  5/21/2014
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2329
mi
from 98109
Baltimore, MD
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization
Status: Enrolling
Updated: 5/21/2014
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients
A Pilot Study to Determine the Effectiveness of Bioelectrical Impedance Analysis as a Clinical Assessment Tool of Nutrition Status in Glioblastoma Multiforme Patients (The BEAM Study [BIA Effectiveness as Assessment Tool for Glioblastoma Multiforme (GBM) Patients])
Status: Enrolling
Updated:  7/31/2014
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients
A Pilot Study to Determine the Effectiveness of Bioelectrical Impedance Analysis as a Clinical Assessment Tool of Nutrition Status in Glioblastoma Multiforme Patients (The BEAM Study [BIA Effectiveness as Assessment Tool for Glioblastoma Multiforme (GBM) Patients])
Status: Enrolling
Updated: 7/31/2014
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated:  8/12/2014
Childrens National Medical Center
2322
mi
from 98109
Washington,
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated: 8/12/2014
Childrens National Medical Center
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated:  8/12/2014
National Cancer Institute
2316
mi
from 98109
Bethesda, MD
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated: 8/12/2014
National Cancer Institute
2316
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated:  8/12/2014
Childrens Hospital Boston, Dana-Farber Cancer Institute.
2485
mi
from 98109
Boston, MA
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated: 8/12/2014
Childrens Hospital Boston, Dana-Farber Cancer Institute.
2485
mi
from 98109
Boston, MA
Click here to add this to my saved trials
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated:  8/12/2014
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Phase 1 Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors
Status: Enrolling
Updated: 8/12/2014
Children's Hospital of Philadelphia
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status: Enrolling
Updated:  11/4/2014
NJ Neuroscience Institute, JFK Medical Center
2390
mi
from 98109
Edison, NJ
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status: Enrolling
Updated: 11/4/2014
NJ Neuroscience Institute, JFK Medical Center
2390
mi
from 98109
Edison, NJ
Click here to add this to my saved trials
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status: Enrolling
Updated:  11/4/2014
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status: Enrolling
Updated: 11/4/2014
Winthrop University Hospital
2417
mi
from 98109
Mineola, NY
Click here to add this to my saved trials
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status: Enrolling
Updated:  11/4/2014
Univ of Rochester Medical Center
2161
mi
from 98109
Rochester, NY
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status: Enrolling
Updated: 11/4/2014
Univ of Rochester Medical Center
2161
mi
from 98109
Rochester, NY
Click here to add this to my saved trials
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status: Enrolling
Updated:  11/4/2014
Hospital Británico
mi
from 98109
Ciudad Autónoma de Buenos Aires,
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Status: Enrolling
Updated: 11/4/2014
Hospital Británico
mi
from 98109
Ciudad Autónoma de Buenos Aires,
Click here to add this to my saved trials
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated:  11/7/2014
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults With Recurrent Glioblastoma Multiforme
Status: Enrolling
Updated: 11/7/2014
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor
Status: Enrolling
Updated:  12/2/2014
Virginia Commonwealth University Massey Cancer Center
2352
mi
from 98109
Richmond, VA
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor
Status: Enrolling
Updated: 12/2/2014
Virginia Commonwealth University Massey Cancer Center
2352
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas
Status: Enrolling
Updated:  1/8/2015
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas
Status: Enrolling
Updated: 1/8/2015
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Derivation of Tumor Specific Hybridomas
Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas
Status: Enrolling
Updated:  1/26/2015
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
Derivation of Tumor Specific Hybridomas
Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas
Status: Enrolling
Updated: 1/26/2015
Dartmouth Hitchcock Medical Center
2392
mi
from 98109
Lebanon, NH
Click here to add this to my saved trials
Derivation of Tumor Specific Hybridomas
Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas
Status: Enrolling
Updated:  1/26/2015
University of Vermont/Vermont Cancer Center
2325
mi
from 98109
Burlington, VT
Derivation of Tumor Specific Hybridomas
Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas
Status: Enrolling
Updated: 1/26/2015
University of Vermont/Vermont Cancer Center
2325
mi
from 98109
Burlington, VT
Click here to add this to my saved trials
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Status: Enrolling
Updated:  4/6/2015
University of Michigan Hospital
1905
mi
from 98109
Ann Arbor, MI
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Status: Enrolling
Updated: 4/6/2015
University of Michigan Hospital
1905
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
A Phase IIa Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Status: Enrolling
Updated:  7/2/2015
Stanford University Cancer Institute
704
mi
from 98109
Stanford, CA
Phase IIa Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
A Phase IIa Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Status: Enrolling
Updated: 7/2/2015
Stanford University Cancer Institute
704
mi
from 98109
Stanford, CA
Click here to add this to my saved trials
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas: Multi-Institutional Trial
Status: Enrolling
Updated:  7/7/2015
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas: Multi-Institutional Trial
Status: Enrolling
Updated: 7/7/2015
Univ of Pennsylvania
2371
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas: Multi-Institutional Trial
Status: Enrolling
Updated:  7/7/2015
Virginia Commonwealth University
2352
mi
from 98109
Richmond, VA
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas: Multi-Institutional Trial
Status: Enrolling
Updated: 7/7/2015
Virginia Commonwealth University
2352
mi
from 98109
Richmond, VA
Click here to add this to my saved trials
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas: Multi-Institutional Trial
Status: Enrolling
Updated:  7/7/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas: Multi-Institutional Trial
Status: Enrolling
Updated: 7/7/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Scottsdale Oncology Program
1114
mi
from 98109
Scottsdale, AZ
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Scottsdale Oncology Program
1114
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Illinois Oncology Research Association
1672
mi
from 98109
Peoria, IL
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Illinois Oncology Research Association
1672
mi
from 98109
Peoria, IL
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Carle Cancer Center
1761
mi
from 98109
Urbana, IL
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Carle Cancer Center
1761
mi
from 98109
Urbana, IL
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Cedar Rapids Oncology Project
1544
mi
from 98109
Cedar Rapids, IA
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Cedar Rapids Oncology Project
1544
mi
from 98109
Cedar Rapids, IA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Iowa Oncology Research Association
1463
mi
from 98109
Des Moines, IA
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Iowa Oncology Research Association
1463
mi
from 98109
Des Moines, IA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
Siouxland Hematology-Oncology
1307
mi
from 98109
Sioux City, IA
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
Siouxland Hematology-Oncology
1307
mi
from 98109
Sioux City, IA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Wichita
1435
mi
from 98109
Wichita, KA
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Wichita
1435
mi
from 98109
Wichita, KA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Ochsner
2095
mi
from 98109
New Orleans, LA
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Ochsner
2095
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Ann Arbor Regional
1901
mi
from 98109
Ann Arbor, MI
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Ann Arbor Regional
1901
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Duluth
1411
mi
from 98109
Duluth, MN
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Duluth
1411
mi
from 98109
Duluth, MN
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
Mayo Clinic Cancer Center
1450
mi
from 98109
Rochester, MN
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
Mayo Clinic Cancer Center
1450
mi
from 98109
Rochester, MN
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CentraCare Clinic
1336
mi
from 98109
Saint Cloud, MN
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CentraCare Clinic
1336
mi
from 98109
Saint Cloud, MN
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Missouri Valley Cancer Consortium
1365
mi
from 98109
Omaha, NE
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Missouri Valley Cancer Consortium
1365
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
Quain & Ramstad Clinic, P.C.
1009
mi
from 98109
Bismarck, ND
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
Quain & Ramstad Clinic, P.C.
1009
mi
from 98109
Bismarck, ND
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Merit Care Hospital
1194
mi
from 98109
Fargo, ND
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Merit Care Hospital
1194
mi
from 98109
Fargo, ND
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
Altru Health Systems
1169
mi
from 98109
Grand Forks, ND
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
Altru Health Systems
1169
mi
from 98109
Grand Forks, ND
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Toledo Community Hospital Oncology Program
1923
mi
from 98109
Toledo, OH
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Toledo Community Hospital Oncology Program
1923
mi
from 98109
Toledo, OH
Click here to add this to my saved trials
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated:  7/7/2015
CCOP - Geisinger Clinical and Medical Center
2273
mi
from 98109
Danville, PA
Irinotecan in Treating Patients With Recurrent Glioma
A Phase II Trial of Irinotecan in Recurrent Glioma
Status: Enrolling
Updated: 7/7/2015
CCOP - Geisinger Clinical and Medical Center
2273
mi
from 98109
Danville, PA
Click here to add this to my saved trials